Ascendis Pharma Seeks FDA Approval for Skytrofa in Adult Growth Hormone Deficiency
核心洞察
Ascendis Pharma has submitted a supplemental Biologics License Application (sBLA) to the FDA for Skytrofa.
The application seeks approval for Skytrofa in treating adults with growth hormone deficiency (搜索) (GHD).
Skytrofa is already approved for pediatric GHD, potentially expanding its market.
Ascendis Pharma has announced the submission of a supplemental Biologics License Application (sBLA) to the U.S. Food and Drug Administration (FDA) seeking approval for Skytrofa (lonapegsomatropin-tcgd) for the treatment of growth hormone deficiency (搜索) (GHD) in adult patients. Skytrofa is currently approved for the treatment of pediatric patients with GHD.
The sBLA is supported by clinical data demonstrating the efficacy and safety of Skytrofa in adults with GHD. Growth hormone deficiency (搜索) in adults can lead to a variety of health issues, including decreased bone density, reduced muscle mass, increased body fat, and cardiovascular problems. Current treatment options often involve daily injections of growth hormone, which can be burdensome for patients.
Skytrofa offers a once-weekly subcutaneous injection, potentially improving adherence and quality of life for patients. The submission marks a significant step toward expanding the availability of Skytrofa to a broader patient population. The FDA will now review the application, and a decision is expected in the coming months. If approved, Skytrofa could provide a valuable new treatment option for adults with GHD, addressing an unmet medical need with a more convenient dosing schedule.